Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) insider Max Reinhardt sold 9,321 shares of the firm’s stock in a transaction dated Tuesday, April 19th. The shares were sold at an average price of $72.25, for a total transaction of $673,442.25. Following the completion of the sale, the insider now owns 24,238 shares in the company, valued at $1,751,195.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
PCRX stock traded up $1.29 during mid-day trading on Wednesday, reaching $75.24. The company’s stock had a trading volume of 444,742 shares, compared to its average volume of 547,079. The company has a current ratio of 1.66, a quick ratio of 1.47 and a debt-to-equity ratio of 0.92. The company’s 50 day moving average is $71.77 and its two-hundred day moving average is $62.50. Pacira BioSciences, Inc. has a fifty-two week low of $45.05 and a fifty-two week high of $82.16. The stock has a market cap of $3.37 billion, a PE ratio of 81.78 and a beta of 0.92.
Pacira BioSciences (NASDAQ:PCRX – Get Rating) last posted its quarterly earnings results on Thursday, February 24th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.60 by $0.37. Pacira BioSciences had a return on equity of 14.94% and a net margin of 7.75%. The firm had revenue of $159.19 million during the quarter, compared to analysts’ expectations of $157.42 million. During the same quarter last year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was up 21.5% on a year-over-year basis. On average, analysts forecast that Pacira BioSciences, Inc. will post 3.04 earnings per share for the current fiscal year.
Several equities research analysts have weighed in on PCRX shares. StockNews.com initiated coverage on Pacira BioSciences in a report on Thursday, March 31st. They issued a “hold” rating for the company. TheStreet downgraded Pacira BioSciences from a “b-” rating to a “c” rating in a research report on Thursday, February 24th. HC Wainwright raised their target price on shares of Pacira BioSciences from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, February 25th. JPMorgan Chase & Co. began coverage on shares of Pacira BioSciences in a report on Monday, January 3rd. They issued an “overweight” rating and a $83.00 price target on the stock. Finally, Wedbush reaffirmed a “buy” rating and set a $94.00 price target (down from $97.00) on shares of Pacira BioSciences in a research report on Saturday, February 26th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $80.63.
Pacira BioSciences Company Profile (Get Rating)
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.
- Get a free copy of the StockNews.com research report on Pacira BioSciences (PCRX)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.